Skip to main content
All

Nuts and Bolts of a Government Investigation

Six-Part Webinar Series for Life Sciences Companies

February 6, 2025
Arnold & Porter Webinar

Part IV: U.S. Congressional Oversight and Investigations of the Life Sciences Industry

Will you be ready if your company becomes the target of a congressional investigation? Congressional investigations are a unique form of inquiry. Unlike civil or criminal proceedings or other forms of government investigations, congressional investigators are not bound by uniform rules of procedure or evidence and operate without any supervision from an impartial authority. Yet, similar to a civil or criminal proceeding, if a party mishandles or misjudges its response to a congressional investigation, that party can face adverse financial, reputational, political, or legal consequences.

Our webinar will cover:

  • A brief history of congressional investigations of biopharmaceutical, medical device, and diagnostic companies
  • Potential areas of oversight scrutiny in the 119th Congress
  • An overview of the congressional oversight investigation process
  • Key considerations and best practices for companies subject to congressional scrutiny
  • Outlook for life sciences industry investigations in the new Congress

We invite you to join the webinar and come with questions.

Upcoming Webinars

Part V: Resolving an Investigation
Date and time to be announced.

Part VI: Hot Topics & Recurring Issues in Life Sciences/Healthcare Enforcement
noon-1 p.m. ET
Dates to be announced.

Watch the Other Webinars in Our Series

Part I: Inception of an Investigation
Learn more and watch the recording here

Part II: Inception of an Investigation
Learn more and watch the recording here

Part III: Issues During an Investigation
Learn more and watch the recording here

Meet the Speakers

Catherine A. Brandon
Partner
Arnold & Porter
Mark Epley
Partner
Arnold & Porter
Daniel A. Kracov
Partner
Arnold & Porter
Bobby McMillin
Managing Director
Arnold & Porter